BioLineRx Ltd. (BLRX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol BLRX
- Company BioLineRx Ltd.
- Price $4.77
- Changes Percentage -9.14
- Change -0.48
- Day Low $4.5
- Day High $5.23
- Year High $35.6
- Year Low $2.3
- Market Cap $14,105,939
- Price Avg 50 EMA (D) $3.16
- Price Avg 200 EMA (D) $11.25
- Exchange NASDAQ
- Volume 46,281
- Average Volume 27,417
- Open $5.16
- Previous Close $5.25
- EPS -6
- PE -0.63
- Earnings Announcement 2025-08-15 12:30:00
- Shares Outstanding $3,721,000
Company brief: BIOLINERX LTD. (BLRX )
- Healthcare
- Biotechnology
- Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA
- https://www.biolinerx.com
- IL
- N/A
- 07-27-2011
- US09071M2052
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
BLRX Corporation News
Why Is Nano-Cap BioLineRx Stock Surging On Friday?
benzinga.com -- BioLineRx Ltd's BLRX poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at the 2025 Am...